CAS NO: 74356-00-6
Cefotetan disodium is a semisynthetic, beta-lactamase resistant,
cephalosporin (cephamycin) antibiotic.
In vitro studies indicate that the bactericidal action of cefotetan
results from an interference of bacterial cell wall synthesis by
inhibiting the cross-linking of peptidoglycan.
Dosage And Administration:
Treatment: Adults: The usual adult dosage is 1 or 2 g administered i.v.
or i.m. every 12 hours for 5 to 10 days.
Proper dosage and route of administration should be determined by the
condition of the patient, severity of the infection and susceptibility
of the causative organism. Therapy may be started while awaiting the
results of susceptibility testing.
The i.v. route is preferable for patients with bacteremia, bacterial
septicemia or other severe or life-threatening infections or for
patients who may be at risk particularly if shock is present or
Availability And Storage: 1 g: Each vial of dry, white to pale
yellow powder contains: cefotetan disodium equivalent to 1 g cefotetan
activity for i.v. and i.m. administration. Nonmedicinal ingredients:
sodium bicarbonate. Sodium: 3.4 mmol (78.7 mg). Vials of 10 mL.
2 g: Each vial of dry, white to pale yellow powder contains: cefotetan
disodium equivalent to 2 g cefotetan activity for i.v. and i.m.
administration. Nonmedicinal ingredients: sodium bicarbonate. Sodium:
6.8 mmol (157.4 mg). Vials of 20 mL.
Store below 25°C and protect from light.
Renal function should be carefully monitored, especially if high dosages
of the aminoglycosides are to be administered or if therapy is
prolonged, because of the potential nephrotoxicity and ototoxicity of
Although, to date, this has not been noted when cefotetan was given
alone, increased nephrotoxicity has been reported following concomitant
administration of cephalosporins and aminoglycoside antibiotics.
However, at the recommended dose, enhancement of nephrotoxicity is
unlikely to be a problem with cefotetan.